Workflow
SHKK(900943)
icon
Search documents
开开实业:关于参加2023年上海辖区上市公司集体接待日暨2023年半年度报告业绩说明会的公告
2023-09-01 07:37
| | | 上海开开实业股份有限公司 关于参加 2023 年上海辖区上市公司集体接待日 暨 2023 年半年度报告业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●会议召开时间:2023 年 9 月 7 日(星期四)下午 14:00-16:30, 其中网络文字互动交流时间为 15:00-16:30 ●会议召开地点:"全景路演"网站(http://rs.p5w.net/) ●会议召开方式:网络文字互动方式 ●投资者可在业绩说明会召开前,扫描本公告中的二维码提前 留言提问。公司将在业绩说明会上对投资者普遍关注的问题进行回 答。 上海开开实业股份有限公司(以下简称"公司")已于 2023 年 8 月 26 日在《上海证券报》《香港商报》及上海证券交易所网站 (www.sse.com.cn)披露了公司《2023 年半年度报告及报告摘要》。 为便于广大投资者更深入全面地了解公司 2023 年半年度经营成果、 财务状况,公司计划于 2023 年 9 月 7 日(周四)下午 14:00-16:30 参 加由 ...
开开B股(900943) - 2023 Q1 - 季度财报
2023-04-27 16:00
Financial Performance - The company's operating revenue for Q1 2023 was CNY 199,595,462.29, representing an increase of 11.50% compared to the same period last year [3] - The net profit attributable to shareholders for Q1 2023 was CNY 9,795,174.23, reflecting a growth of 16.06% year-over-year [3] - Basic earnings per share for Q1 2023 were CNY 0.040, up by 14.29% from the previous year [3] - Total operating revenue for Q1 2023 reached ¥199,595,462.29, an increase of 11.0% compared to ¥179,002,475.46 in Q1 2022 [11] - Net profit for Q1 2023 was ¥9,080,552.75, representing a 24.0% increase from ¥7,320,355.27 in Q1 2022 [11] - Earnings per share for Q1 2023 were ¥0.040, compared to ¥0.035 in Q1 2022, marking a 14.3% increase [11] Cash Flow - The net cash flow from operating activities was negative at CNY -24,761,380.76, indicating a significant cash outflow [3] - Cash flow from operating activities showed a net outflow of ¥24,761,380.76 in Q1 2023, worsening from a net outflow of ¥17,377,534.45 in Q1 2022 [14] - Investment activities resulted in a net cash outflow of ¥50,014,416.03 in Q1 2023, compared to a smaller outflow of ¥512,015.94 in Q1 2022 [14] - Financing activities also showed a net cash outflow of ¥3,732,580.00 in Q1 2023, an improvement from an outflow of ¥7,164,163.19 in Q1 2022 [14] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,137,627,439.76, a decrease of 5.77% from the end of the previous year [3] - As of March 31, 2023, total assets amounted to ¥1,137,627,439.76, a decrease of approximately 5.77% from ¥1,207,255,505.50 on December 31, 2022 [8] - Current assets totaled ¥524,013,720.38, down 11.06% from ¥589,293,001.32 at the end of 2022 [8] - Total current liabilities were ¥358,026,106.61, a reduction of 17.73% from ¥435,213,299.44 [9] - The total liabilities amounted to ¥550,295,468.92, a decrease of 12.52% from ¥629,004,087.41 [9] Equity and Investments - The company's equity attributable to shareholders increased to ¥578,377,443.33, up from ¥568,582,269.10, reflecting a growth of 1.40% [9] - The company’s investment income increased by 129.23% compared to the previous year, attributed to gains from Shanghai Jing'an Pharmaceutical Co., Ltd. [5] - The company reported an increase in investment income to ¥1,358,685.13 in Q1 2023, up from ¥592,729.19 in Q1 2022 [11] Other Financial Metrics - The weighted average return on equity increased by 0.12 percentage points to 1.71% [3] - The company reported a significant increase in credit impairment losses by 425.94% due to a rise in bad debt provisions [5] - The company received government subsidies totaling CNY 5,547,800 during the reporting period, including CNY 3,847,900 on February 17, 2023 [7] - The company reported a decrease in inventory to ¥69,068,809.18, down 22.24% from ¥88,718,754.49 [8] - Cash and cash equivalents decreased to ¥222,422,833.06, a decline of 26.06% compared to ¥300,932,076.82 [8] - Accounts receivable stood at ¥150,113,420.39, down 9.23% from ¥165,407,141.33 [8] - Accounts payable decreased to ¥142,872,558.90, down 31.67% from ¥209,334,956.57 [9] - The non-current assets totaled ¥613,613,719.38, slightly down from ¥617,962,504.18, indicating a decrease of 0.56% [8]
开开实业:关于参加2023年上海辖区上市公司年报集体业绩说明会的公告
2023-04-24 09:20
| | | 上海开开实业股份有限公司 关于参加 2023 年上海辖区上市公司 年报集体业绩说明会的公告 ●会议召开地点:上证路演中心 (http://roadshow.sseinfo.com) ●会议召开方式:网络文字互动方式 ●投资者可在 2023 年 5 月 6 日 16:00 前 , 通 过 公 司 邮 箱 dm@chinesekk.com提前留言提问。公司将在业绩说明会上对投资者普 遍关注的问题进行回答。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●会议召开时间:2023 年 5 月 10 日(星期三)下午 15:00-17:00 上海开开实业股份有限公司(以下简称"公司")已于 2023 年 3 月 30 日在《上海证券报》《香港商报》及上海证券交易所网站 (www.sse.com.cn)披露了公司《2022 年年度报告及摘要》。并将于 2023 年 4 月 28 日在《上海证券报》《香港商报》及上海证券交易所 网站(www.sse.com.cn)披露公司《2023 年第一季度报告》。为进一 步 ...
开开B股(900943) - 2022 Q1 - 季度财报
2022-04-27 16:00
Financial Performance - The company's operating revenue for Q1 2022 was CNY 179,002,475.46, representing a decrease of 6.53% compared to the same period last year[3]. - Net profit attributable to shareholders of the listed company reached CNY 8,440,101.50, a significant increase of 507.68% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 2,941,866.39, down 35.83% compared to the previous year[3]. - The basic earnings per share for the period was CNY 0.035, reflecting an increase of 483.33% year-on-year[3]. - The company reported a net cash flow from operating activities of CNY -17,377,534.45, which is not applicable for comparison[3]. - Total operating revenue for Q1 2022 was ¥179,002,475.46, a decrease of 6.9% compared to ¥191,512,157.42 in Q1 2021[13]. - Net profit for Q1 2022 reached ¥7,320,355.27, compared to a net loss of ¥435,018.69 in Q1 2021, marking a significant turnaround[13]. - The profit attributable to shareholders of the parent company was ¥8,440,101.50 in Q1 2022, up from ¥1,388,901.35 in Q1 2021[13]. - Basic and diluted earnings per share for Q1 2022 were both ¥0.035, compared to ¥0.006 in Q1 2021[13]. - The company reported a total comprehensive income of ¥7,320,355.27 for Q1 2022, compared to ¥24,167.91 in Q1 2021[13]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,047,121,528.60, a decrease of 1.49% from the end of the previous year[3]. - Current assets decreased to CNY 407,472,925.84 from CNY 416,604,983.44, reflecting a decline of approximately 3.1%[10]. - Total liabilities decreased to CNY 499,818,566.71 from CNY 516,427,723.90, representing a reduction of about 3.2%[11]. - The company's cash and cash equivalents were CNY 148,449,189.59, down from CNY 173,503,223.58, indicating a decrease of approximately 14.5%[10]. - Total assets as of March 31, 2022, amounted to CNY 1,047,121,528.60, a decrease from CNY 1,062,971,330.52 as of December 31, 2021[10]. - Accounts receivable increased to CNY 127,396,628.75 from CNY 97,686,947.91, showing a growth of about 30.3%[10]. - Inventory decreased to CNY 85,518,764.76 from CNY 90,743,933.02, a decline of approximately 5.0%[10]. - The company reported a decrease in accounts payable from CNY 141,987,690.86 to CNY 131,208,713.29, a reduction of about 7.0%[11]. - Total equity increased slightly to CNY 547,302,961.89 from CNY 546,543,606.62, reflecting a marginal growth[11]. - The company’s retained earnings increased to CNY 222,233,819.90 from CNY 220,354,718.40, indicating a growth of approximately 0.8%[11]. Government Subsidies and Financial Activities - The company received government subsidies amounting to CNY 1,824,823.46, which are closely related to its normal business operations[4]. - The company incurred a financial expense of ¥1,442,664.33 in Q1 2022, compared to a financial income of ¥2,479,606.42 in Q1 2021[13]. - The company’s sales expenses decreased to ¥20,821,678.99 in Q1 2022 from ¥24,726,326.94 in Q1 2021, reflecting a cost control strategy[13]. Shareholder and Ownership Structure - The company has no significant related party transactions among the top shareholders, ensuring transparency in ownership structure[8]. - The weighted average return on equity was 1.59%, an increase of 1.32 percentage points compared to the end of the previous year[3]. - The equity attributable to shareholders of the listed company was CNY 537,310,591.98, an increase of 0.35% compared to the end of the previous year[3]. - The company experienced a 250.17% increase in notes receivable, indicating an increase in bank acceptance notes that were endorsed but not yet due at the end of the reporting period[6].
开开B股(900943) - 2021 Q3 - 季度财报
2021-10-28 16:00
Financial Performance - Q3 2021 revenue was CNY 151,085,329.25, a decrease of 21.97% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 1,204,092.91, down 23.06% year-on-year[3] - Basic earnings per share for the quarter was CNY 0.005, a decline of 28.57% compared to the previous year[3] - Total operating revenue for the first three quarters of 2021 was ¥487,143,426.54, a decrease of 17.1% compared to ¥587,805,430.52 in the same period of 2020[13] - Net profit for the first three quarters of 2021 was ¥3,816,631.48, a decline of 20.5% from ¥4,802,727.21 in 2020[13] - The company reported a total comprehensive income of ¥1,058,193.67 for the first three quarters of 2021, down from ¥5,355,874.38 in 2020[13] - The company recorded a decrease in sales revenue from customers, totaling ¥521,528,804.85 in the first three quarters of 2021, down 11.2% from ¥587,328,609.72 in 2020[15] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,046,521,231.02, an increase of 0.29% from the end of the previous year[3] - As of September 30, 2021, the company's total current assets amounted to ¥595,611,567.23, an increase from ¥567,332,519.85 as of December 31, 2020, representing an increase of approximately 5.4%[10] - The company's total non-current assets decreased to ¥450,909,663.79 from ¥476,136,545.37, reflecting a decrease of about 5.3%[10] - Total liabilities as of September 30, 2021, were ¥518,311,998.26, slightly down from ¥522,666,443.41 at the end of 2020, indicating a decrease of approximately 0.7%[11] - The company's total equity increased to ¥528,209,232.76 from ¥520,802,621.81, showing an increase of about 1.5%[11] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY -20,688,337.92, a decrease of 216.18% compared to the previous year[3] - Cash flow from operating activities for the first three quarters of 2021 was negative at -¥20,688,337.92, compared to positive cash flow of ¥17,806,878.28 in 2020[15] - Investment activities generated a net cash outflow of -¥22,596,571.36 in the first three quarters of 2021, slightly worse than -¥21,680,994.79 in 2020[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,118[7] - Basic earnings per share for the first three quarters of 2021 increased to ¥0.029 from ¥0.023 in 2020, representing a growth of 26.1%[13] Operational Adjustments - The company’s subsidiary implemented business adjustments, leading to a reduction in operating expenses[6] - The company has authorized the management to sell stock assets to improve liquidity and optimize asset structure, indicating a strategic move to enhance financial flexibility[8]
开开B股(900943) - 2021 Q2 - 季度财报
2021-08-27 16:00
Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥336.06 million, a decrease of 14.75% compared to ¥394.19 million in the same period last year[22]. - The net profit attributable to shareholders for the first half of 2021 was approximately ¥5.94 million, an increase of 51.57% from ¥3.92 million in the previous year[22]. - The basic earnings per share for the first half of 2021 was ¥0.024, representing a 20% increase from ¥0.02 in the same period last year[20]. - The weighted average return on equity increased to 1.15%, up by 0.39 percentage points from 0.76% in the previous year[20]. - The net cash flow from operating activities was approximately ¥25.62 million, a decrease of 31.42% compared to ¥37.36 million in the same period last year[22]. - The company's total assets as of June 30, 2021, amounted to CNY 1,057.26 million, an increase of CNY 13.79 million or 1.32% from the beginning of the year[37]. - For the first half of 2021, the company achieved operating revenue of CNY 336.06 million, a decrease of CNY 58.13 million or 14.75% year-on-year[37]. - The net profit attributable to the parent company for the same period was CNY 5.94 million, an increase of CNY 2.02 million or 51.57% compared to the previous year[37]. - Revenue for the first half of 2021 was CNY 336,058,097.29, a decrease of 14.75% compared to CNY 394,191,825.64 in the same period last year[47]. - Operating costs decreased by 19.50% to CNY 242,586,193.32 from CNY 301,336,057.58, primarily due to reduced sales revenue[48]. - Management expenses increased by 17.79% to CNY 43,806,775.62, attributed to comprehensive reforms in the apparel sector[48]. Strategic Initiatives - The company has optimized its pharmaceutical segment and adjusted its sales structure to reduce the proportion of low-margin products, leading to increased profitability[21]. - The company is focusing on optimizing its pharmaceutical segment and adjusting its sales structure to reduce the proportion of low-yield products, thereby enhancing economic efficiency[37]. - The company is actively exploring the integration of traditional Chinese medicine with health management, aiming to drive the "big health" industry development[27]. - The company has implemented a strategic transformation towards the "big health" sector, leveraging its dual brand strategy with "Lei Yun Shang" and "Kai Kai" to enhance market influence[36]. - The company aims to strengthen its core business efficiency and seek new revenue and profit growth points to support its transformation and high-quality development[36]. - The company is actively exploring new growth points in the DTP pharmacy business and has launched a health service point in the North City High-tech outpatient department, becoming one of the first 58 "employee health service points" in Shanghai[41]. - The company has optimized its business layout and compressed levels to improve resource allocation, disposing of ineffective assets to free up more resources for core business expansion[42]. - The company has implemented a comprehensive reform of its garment trade sector, enhancing product differentiation and service professionalism to increase market share[44]. - The company has introduced new product lines, including wrinkle-free shirts and cashmere-silk scarves, to meet changing consumer demands[44]. Operational Challenges - The company faced various operational risks, which have been detailed in the management discussion and analysis section of the report[6]. - The company is facing risks related to macroeconomic changes and strict healthcare policies that may impact its pharmaceutical segment[66]. - The company is facing significant challenges in performance due to the adjustment of its development focus and external market conditions, including the ongoing impact of the pandemic[68]. - The ongoing global pandemic presents uncontrollable risks, with potential localized outbreaks affecting business operations[67]. - The company’s sales channels still heavily rely on traditional store sales, with e-commerce sales accounting for a smaller proportion[67]. Corporate Governance and Shareholder Information - The company did not propose any interim profit distribution or capital reserve transfer to share capital during the reporting period[4]. - The total number of ordinary shareholders at the end of the reporting period was 26,620[91]. - The largest shareholder, Shanghai Kaikai (Group) Co., Ltd., held 64,409,783 shares, representing 26.51% of total shares[94]. - The top ten shareholders include a mix of state-owned and individual investors, with no significant changes in shareholding structure during the reporting period[90][94]. - There were no major guarantees or significant contracts reported during the period[90][91]. - No changes in the company's share capital structure were noted[90]. - The company did not report any changes in the controlling shareholder or actual controller during the reporting period[98]. Environmental and Social Responsibility - The company is committed to carbon neutrality and has implemented innovative technologies to reduce carbon emissions in production processes[45]. - The company promotes a paperless office environment and encourages employees to adopt "green travel" practices to contribute to sustainable development[79]. - The company has committed to providing a total of up to 1.5 million yuan in aid over five years to support rural revitalization efforts in Yunnan Province[81]. Financial Management and Accounting Policies - The financial statements are prepared based on the going concern assumption, with no significant factors affecting the company's ability to continue operations identified[128]. - The accounting policies comply with the requirements of the enterprise accounting standards, ensuring a true and complete reflection of the company's financial status[129]. - The company recognizes goodwill when the initial investment cost of long-term equity investments exceeds the fair value of identifiable net assets acquired in a business combination[135]. - The company consolidates financial statements based on control, including all subsidiaries under its control in the consolidated financial statements[136]. - The company measures financial assets at fair value upon initial recognition, with transaction costs accounted for differently based on the asset classification[142]. - The company recognizes expected credit losses based on historical data, current conditions, and forecasts of future economic conditions, using a probability-weighted approach[145]. Investment and Subsidiary Performance - The company has established a new subsidiary, "Shanghai Leixi Lean Supply Chain Management Co., Ltd.," which won the bid for the medical consumables supply chain management service project in Jing'an District[41]. - Shanghai Lei Yun Shang Pharmaceutical West District Co., Ltd. generated a revenue of 65.88 million RMB and a net profit of 0.39 million RMB during the reporting period[64]. - Shanghai Kaikai Garment Co., Ltd. reported a revenue of 23.69 million RMB but incurred a loss of 5.43 million RMB due to business restructuring[61]. - Shanghai Lei Xi New Special Pharmacy Co., Ltd. reported a revenue of 15.54 million RMB with a loss of 1.82 million RMB during the reporting period[65].
开开B股(900943) - 2021 Q1 - 季度财报
2021-04-28 16:00
Financial Performance - Operating revenue for the current period was CNY 191,512,157.42, down 8.81% year-on-year [6]. - Net profit attributable to shareholders was CNY 1,388,901.35, a decrease of 39.69% compared to the same period last year [6]. - Basic earnings per share decreased by 40.00% to CNY 0.006 from CNY 0.01 [6]. - The company's operating profit for Q1 2021 was ¥3.43 million, down 46.4% from ¥6.41 million in Q1 2020 [24]. - The company reported a total profit of ¥3.38 million in Q1 2021, a decrease of 46.8% from ¥6.35 million in Q1 2020 [24]. - Other comprehensive income after tax for Q1 2021 was ¥459,186.60, down 28% from ¥636,711.63 in Q1 2020 [24]. - Investment income for Q1 2021 was -¥843,103.28, compared to a gain of ¥839,283.53 in Q1 2020 [24]. - The company reported a credit impairment loss of -¥1,905,339.46 in Q1 2021, an improvement from -¥4,709,880.93 in Q1 2020 [24]. Cash Flow - The net cash flow from operating activities was negative CNY 24,993,754.92, worsening from negative CNY 17,737,668.61 in the previous year [6]. - The net cash flow from operating activities for Q1 2021 was approximately -¥25 million, worsening from -¥17.7 million in Q1 2020 [30]. - The total cash outflow from operating activities in Q1 2021 was approximately ¥222 million, compared to ¥219 million in Q1 2020, indicating a slight increase [30]. - The company reported a net cash flow from investment activities of approximately ¥432,000 in Q1 2021, a significant decrease from ¥37 million in Q1 2020 [30]. - The cash inflow from financing activities in Q1 2021 was approximately ¥12 million, while the cash outflow was about ¥2.8 million, resulting in a net cash flow of approximately ¥9.2 million [30]. - The net cash flow from financing activities was positive at ¥9,191,657.10, reflecting increased cash from minority shareholder investments [14]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,031,765,535.38, a decrease of 1.12% compared to the end of the previous year [6]. - The total prepayments increased by 251.06% to ¥3,063,621.06 compared to the end of last year [11]. - Inventory decreased by 29.46% to ¥68,453,820.17 due to sales and reduced stock levels [12]. - Other current assets dropped by 82.65% to ¥544,778.84 as a result of reclassification under new leasing standards [11]. - Current liabilities decreased from ¥305,042,080.53 to ¥266,141,130.80, a reduction of approximately 12.8% [18]. - Total liabilities decreased from ¥522,666,443.41 to ¥499,408,253.19, a reduction of about 4.4% [18]. - Total equity increased from ¥520,802,621.81 to ¥532,357,282.19, an increase of about 2.9% [18]. - Cash and cash equivalents decreased from ¥80,733,624.23 to ¥76,026,337.47, a decline of approximately 9.2% [20]. - Total current assets decreased slightly to CNY 567,332,519.85 from CNY 565,667,457.92, a reduction of CNY 1,665,061.93 [33]. - Total liabilities increased to CNY 552,227,765.06, up by CNY 29,561,321.65 from CNY 522,666,443.41 [34]. Shareholder Information - The total number of shareholders at the end of the reporting period was 26,350 [10]. - The largest shareholder, Shanghai Kaikai (Group) Co., Ltd., held 26.51% of the shares [10]. - The minority equity increased by 225.47% to ¥14,627,906.45 due to new investments from minority shareholders [11]. - The company’s minority interests decreased from CNY 4.49 billion to CNY 4.45 billion, a decrease of CNY 42.57 million [40]. Management and Expenses - Management expenses increased by 56.35% to ¥28,916,787.73, attributed to reform costs and rising labor costs [14]. - The company experienced a significant increase in management expenses, which rose to ¥28.92 million in Q1 2021 from ¥18.49 million in Q1 2020, an increase of 56.5% [24].
开开B股(900943) - 2020 Q4 - 年度财报
2021-03-25 16:00
Financial Performance - The company's operating revenue for 2020 was approximately RMB 761.82 million, a decrease of 12.47% compared to RMB 870.40 million in 2019[24]. - The net profit attributable to shareholders for 2020 was RMB 13.67 million, down 37.77% from RMB 21.98 million in 2019[24]. - The net profit after deducting non-recurring gains and losses was RMB 2.27 million, a decline of 76.27% from RMB 9.57 million in 2019[24]. - Basic earnings per share for 2020 were RMB 0.06, a decrease of 33.33% compared to RMB 0.09 in 2019[25]. - The company achieved a total revenue of 761.82 million yuan in 2020, with the apparel segment declining by 36.67% to 83.18 million yuan and the pharmaceutical segment decreasing by 8.07% to 674.91 million yuan[49]. - The net profit attributable to shareholders was 13.67 million yuan, a decrease of 37.77% compared to the previous year, reflecting a reduction of 8.30 million yuan[49]. - The company reported a total return of 696,000 yuan from new stock subscriptions and treasury bond reverse repos, enhancing the efficiency of idle funds[52]. - The company reported a revenue of ¥761,821,632.96, a decrease of 12.47% compared to the previous year[55]. - The operating costs decreased by 15.92% to ¥568,346,148.97, leading to an improved gross margin[55]. - The apparel segment experienced a revenue decline of 37.88%, with a gross margin of 9.06%, down 2.24 percentage points from the previous year[56]. Cash Flow and Assets - The net cash flow from operating activities increased significantly to RMB 81.66 million, up 293.96% from RMB 20.73 million in 2019[24]. - The total assets at the end of 2020 were approximately RMB 1.04 billion, a slight increase of 0.27% from RMB 1.04 billion at the end of 2019[24]. - The company's net assets attributable to shareholders at the end of 2020 were RMB 516.31 million, a marginal increase of 0.28% from RMB 514.87 million at the end of 2019[24]. - The company's cash and cash equivalents at the end of the period were 268,152,054.81 RMB, which is 25.70% of total assets, up from 22.25% in the previous period[71]. - The value of trading financial assets increased by CNY 3,088.87 million to CNY 81,958.13 million as of December 31, 2020[80]. - Total current assets increased to ¥567,332,519.85 in 2020 from ¥541,856,147.52 in 2019, representing a growth of approximately 4.4%[194]. - Cash and cash equivalents rose to ¥268,152,054.81 in 2020, up from ¥231,517,904.83 in 2019, indicating an increase of about 15.8%[194]. - Trading financial assets increased significantly to ¥81,958,127.32 in 2020 from ¥51,069,381.77 in 2019, marking a growth of approximately 60.5%[194]. Business Challenges and Strategies - The company faced challenges in its pharmaceutical segment due to policies and the impact of the COVID-19 pandemic, leading to a decline in traditional sales revenue[25]. - The apparel segment faced significant negative impacts on revenue and profitability due to the dual blows of lost foreign trade orders and the pandemic[26]. - The company is focusing on restructuring and reforming its apparel business to improve operational efficiency amid a challenging market environment[37]. - The company is exploring expansion into three core business areas: pharmaceutical health, medical health, and elderly care health[25]. - The company aims to transform towards the big health industry by leveraging its traditional Chinese medicine distribution platform and developing new products and sales channels[25]. - The company is focusing on the "big health" transformation strategy, aiming to enhance its health service capabilities and leverage the "Healthy China 2030" initiative[50]. - The company plans to continue its market expansion and product development strategies to enhance its competitive position in the industry[86]. - The company aims to enhance its operational efficiency and adjust its garment business strategy in response to market conditions, focusing on improving economic benefits[98]. Corporate Governance and Management - The company has introduced key personnel, including a new deputy general manager and a financial director, to strengthen its management team and improve decision-making efficiency[50]. - The company has a diverse management team with extensive experience in various sectors[161]. - The independent directors have backgrounds in academia and law, enhancing governance[161]. - The company adheres to legal requirements for corporate governance, ensuring the protection of shareholder rights and maintaining operational independence among the board and management[175]. - The company’s management performance evaluation is primarily based on operational performance, ensuring alignment with long-term shareholder interests[181]. Legal and Compliance Issues - The company is currently facing significant litigation issues, including a dispute with China Everbright Bank regarding a bill of exchange[123]. - The total litigation costs incurred by the company amount to CNY 260,410 for case acceptance fees, CNY 250,520 for property preservation fees, and CNY 80,000 for assessment fees, all borne by China Cinda Asset Management Co., Ltd.[123]. - The company faced legal disputes involving asset freezes and property seizures, with a total limit of RMB 50 million for properties located at Nanjing West Road, Shanghai[124]. - The company has been involved in multiple lawsuits regarding the validity of credit and pledge contracts, with the latest ruling confirming the contracts' validity[125]. - The company has received notifications from law enforcement regarding the ongoing investigation into economic crimes linked to its former management[125]. Social Responsibility and Community Engagement - The company provided rent relief of RMB 2.6614 million to support small and medium-sized enterprises in response to pandemic-related operational difficulties[26]. - The company actively engaged in social responsibility by donating clothing and supporting pandemic relief efforts[53]. - The company donated RMB 300,000 to assist a poverty-stricken village in Yunnan Province as part of its corporate social responsibility efforts[139]. - The company has maintained a stable relationship with its partner villages under the "Hundred Enterprises and Hundred Villages" poverty alleviation initiative[139]. - The company has actively participated in local pandemic prevention efforts, receiving recognition for its contributions[139]. Future Outlook - The company has provided a positive outlook for the next quarter, projecting a revenue increase of 25%[164]. - New product launches are expected to contribute an additional 300 million RMB in revenue over the next fiscal year[165]. - The company is investing in new technology development, allocating 100 million RMB towards R&D initiatives[166]. - Market expansion plans include entering two new provinces, which are projected to increase market share by 10%[162]. - A new marketing strategy is being implemented, aiming to increase brand awareness by 30% within the next six months[164].
开开B股(900943) - 2020 Q3 - 季度财报
2020-10-29 16:00
Financial Performance - Operating revenue for the first nine months was CNY 587,805,430.52, representing an 8.20% decrease year-on-year[8] - Net profit attributable to shareholders decreased by 61.32% to CNY 5,486,879.65 for the first nine months[8] - Basic earnings per share dropped by 66.67% to CNY 0.02[8] - The company anticipates a cumulative net profit decline of approximately 70% compared to the previous year due to the impact of COVID-19 on retail operations[13] - Total operating revenue for Q3 2020 was ¥193.61 million, a decrease of 2.6% compared to ¥198.92 million in Q3 2019[21] - Net profit for Q3 2020 was ¥1.27 million, down 51.5% from ¥2.61 million in Q3 2019[21] - The company reported a total profit of ¥3.03 million for Q3 2020, a decrease of 55.8% from ¥6.84 million in Q3 2019[21] - The total comprehensive income for Q3 2020 was ¥2.80 million, down 61.2% from ¥7.23 million in Q3 2019[21] - The company's total revenue for the first three quarters of 2020 was ¥587.81 million, a decrease of 8.2% from ¥640.31 million in the same period of 2019[21] - The net profit for the first three quarters of 2020 was ¥19,964,555.75, down from ¥24,030,421.81 in the same period of 2019, representing a decline of 16.5%[24] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 17,806,878.28, a significant improvement from a negative cash flow of CNY -9,239,686.71 in the same period last year[8] - The company reported a net cash flow from operating activities of ¥17,806,878.28 for the first three quarters of 2020, a significant improvement from a negative cash flow of ¥9,239,686.71 in the same period of 2019[27] - Cash inflow from investment activities totaled CNY 182,274,369.18, down 35.3% from CNY 281,635,835.21 in 2019[29] - The net cash flow from investment activities was -CNY 4,392,917.89, compared to a positive cash flow of CNY 42,369,210.93 in the same period last year[29] - The total cash and cash equivalents at the end of the period were CNY 74,624,522.13, compared to CNY 40,084,162.25 at the end of the same period last year[29] - The company experienced a net decrease in cash and cash equivalents of -CNY 17,053,736.37, contrasting with a net increase of CNY 9,226,720.01 in the same period last year[29] Assets and Liabilities - Total assets decreased by 3.32% compared to the end of the previous year, amounting to CNY 1,006,031,193.48[8] - The company's total liabilities decreased from ¥520,469,182.88 to ¥487,349,984.85, reflecting a reduction in short-term borrowings and accounts payable[17] - Current liabilities decreased to RMB 113,978,845.76 from RMB 129,188,829.18, reflecting a reduction of approximately 11.5%[19] - Total liabilities decreased from RMB 173,377,802.86 to RMB 157,963,384.01, indicating a decline of about 8.8%[19] - Owner's equity increased to RMB 491,282,407.46 from RMB 476,663,821.14, representing a growth of approximately 3.1%[19] - The company’s cash and cash equivalents decreased from ¥231,517,904.83 to ¥210,989,526.88, indicating a liquidity contraction[16] Shareholder Information - The total number of shareholders at the end of the reporting period was 28,118[9] - The largest shareholder, Shanghai Kaikai (Group) Co., Ltd., holds 26.51% of the shares[9] Operating Costs and Expenses - Total operating costs for Q3 2020 were ¥202.23 million, an increase of 7.1% from ¥188.74 million in Q3 2019[21] - The company incurred a credit impairment loss of ¥10.33 million in Q3 2020, compared to a gain of ¥7.70 million in Q3 2019[21] - The company’s management expenses increased to ¥7,065,988.50 in the first three quarters of 2020, up from ¥6,909,766.18 in the same period of 2019[24] - The financial expenses for Q3 2020 were reported at ¥10,410,886.57, a significant increase compared to a negative financial expense of -¥7,871,275.45 in Q3 2019[24] Investment and Other Income - Non-operating income and expenses totaled CNY 3,145,360.56 for the current period[7] - The company received government subsidies amounting to CNY 1,527,214.84 during the reporting period[7] - Investment income dropped by 63.59%, totaling ¥1,823,160.47, attributed to increased investment losses from joint ventures[11]
开开B股(900943) - 2020 Q2 - 季度财报
2020-08-19 16:00
Financial Performance - The company's operating revenue for the first half of 2020 was ¥394,191,825.64, a decrease of 10.69% compared to ¥441,393,740.09 in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2020 was ¥3,921,996.69, down 65.79% from ¥11,463,557.33 in the previous year[20]. - The basic earnings per share for the first half of 2020 was ¥0.02, a decrease of 60.00% from ¥0.05 in the same period last year[21]. - The total profit for the period was 9.93 million yuan, down 89.98 million yuan from 18.93 million yuan in the previous year, primarily due to increased losses from the Beiqu High-tech Clinic and the impact of the COVID-19 pandemic[39]. - The net profit attributable to the parent company was 3.92 million yuan, a decrease of 75.42 million yuan or 65.79% year-on-year[39]. - The net profit after deducting non-recurring gains and losses was -¥1,773,208.45, compared to ¥5,614,384.68 in the same period last year, reflecting a decrease of 131.58%[20]. - The company anticipates a cumulative net profit decline of approximately 70% compared to the previous year due to the impact of COVID-19 and related operational disruptions[66]. Cash Flow and Assets - The net cash flow from operating activities increased by 15.07% to ¥37,364,268.31 compared to ¥32,471,506.93 in the same period last year[20]. - The company's total assets decreased by 3.72% to ¥1,001,941,652.36 from ¥1,040,613,604.35 at the end of the previous year[20]. - The company's net assets attributable to shareholders at the end of the reporting period were ¥510,999,051.11, a slight decrease of 0.75% from ¥514,866,002.21 at the end of the previous year[20]. - Total assets at the end of the reporting period amounted to ¥1,003,000,000, with cash and cash equivalents representing 18.54% of total assets, an increase from 16.35% in the previous year[54]. - Accounts receivable decreased by 8.38% to ¥105,633,916.99, compared to ¥115,297,751.84 in the same period last year[54]. - Inventory decreased by 14.83% to ¥79,478,281.78, down from ¥93,322,249.51 year-on-year[54]. - The company's cash and cash equivalents decreased to CNY 185,716,350.16 from CNY 231,517,904.83, representing a decline of about 19.8%[104]. Impact of COVID-19 - The company faced significant impacts on its business due to the COVID-19 pandemic, affecting retail operations and order volumes in both the apparel and pharmaceutical sectors[20]. - The retail industry faced significant challenges due to the COVID-19 pandemic, with a reported decline in retail sales of 20.5% in January-February 2020[32]. - The company's overall business operations faced significant challenges due to reduced patient visits and hospital restrictions during the pandemic[66]. - The apparel segment's offline customer traffic was heavily impacted, leading to a sharp decline in foreign trade processing orders[66]. Strategic Initiatives - The company is actively pursuing a "big health" strategic transformation, integrating medicine, healthcare, and elderly care services[29]. - The company has established a drug distribution platform to enhance its operational efficiency in the pharmaceutical sector[29]. - The company is focusing on brand building and e-commerce development to adapt to the changing retail landscape[35]. - The company has actively expanded its online sales channels, launching promotional activities on platforms like "Ele.me" to boost sales during the pandemic[42]. - The company has introduced new products such as epidemic prevention sachets and health teas, which have attracted market attention[42]. Legal and Compliance Issues - The company is involved in a significant litigation case with China Everbright Bank regarding a bill dispute, which has been ongoing since 2005[76]. - The Shenzhen Intermediate People's Court ruled against the company's claims, leading to an appeal to the Guangdong High People's Court[76]. - The company has requested the withdrawal of its appeal based on the Civil Procedure Law of the People's Republic of China[76]. - The litigation has incurred costs including 260,410 yuan for case acceptance fees, 250,520 yuan for property preservation fees, and 80,000 yuan for evaluation fees, all borne by China Cinda Asset Management Co., Ltd.[76]. - The company has been under scrutiny for economic crime allegations, which could affect its market reputation and operational strategies moving forward[77]. - The company is focused on resolving legal disputes to ensure the stability of its financial assets and business operations[77]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,520[91]. - The largest shareholder, Shanghai Kaikai (Group) Co., Ltd., holds 64,409,783 shares, representing 26.51% of the total shares[93]. - Shanghai Jing'an State-owned Assets Management Co., Ltd. is the second-largest shareholder with 6,000,000 shares, accounting for 2.47%[93]. Accounting and Financial Reporting - The financial statements are prepared based on the going concern principle and the accrual basis of accounting, ensuring reliable measurement of accounting elements[126]. - The company confirms that there are no significant factors affecting its ability to continue as a going concern within the next 12 months[127]. - The financial statements comply with the accounting standards issued by the Ministry of Finance, reflecting the company's financial position and operating results accurately[128]. - The company has not reported any major contracts or guarantees that would impact its financial standing[83]. - There were no significant accounting errors that required restatement during the reporting period[88].